Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have (borderline) resectable pancreatic cancer [(B)RPC] at diagnosis. Upfront resection with adjuvant chemotherapy has long been the standard of care for these patients. However, although surgical quality has improved, still about...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Quisette P., O'Reilly, Eileen M., van Eijck, Casper H. J., Groot Koerkamp, Bas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005204/
https://www.ncbi.nlm.nih.gov/pubmed/32083002
http://dx.doi.org/10.3389/fonc.2020.00041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005204/
https://www.ncbi.nlm.nih.gov/pubmed/32083002
http://dx.doi.org/10.3389/fonc.2020.00041

Ejemplares similares